How to identify patients with high-risk HR-positive/HER2- negative breast cancer in the absence of gene expression platforms 

Fernández Martínez, Aranzazu (Date of defense: 2021-07-16)

[eng] HR-positive/HER2-negative (HR+/HER2-) is the most common breast cancer type, and it is a molecular heterogenic disease. This heterogeneity has direct prognostic and predictive implications in both early and advanced ...